About us
Liminatus Pharma is a pre‑clinical‑stage immuno‑oncology company pioneering the development of a second‑generation CD47‑blockade antibody designed to prevent the severe anemia and thrombocytopenia that have limited first‑generation CD47 therapies. Building on more than a decade of CD47‑blockade immunotherapy development and lessons from clinical setbacks across the field, we engineered an upgraded CD47‑blockade antibody—IBA101—which is being advanced as a next‑generation immuno‑oncology therapy with broad applicability across a range of solid tumors.
In parallel with IBA101, we are expanding our portfolio with a suite of rationally designed, multi‑specific CAR‑T cell therapies targeting both solid and hematologic malignancies. Our current pipeline includes a CD19×CD22 Dual CAR‑T for hematologic cancers, an MSLN×CD276 bicistronic CAR‑T for solid tumors, and a CD19×CD22×CS1 trivalent CAR‑T for hematologic cancers, reflecting our strategy to address diverse tumor types while overcoming resistance mechanisms and antigen escape.
By integrating second‑generation CD47 blockade with advanced CAR‑T platforms, we aim to build a differentiated, next‑generation immuno‑oncology company capable of delivering durable clinical benefit across multiple cancer indications.
Our mission is to develop novel immunotherapies that restore immune balance and broaden treatment options for cancer patients. We view the human immune system as a finely tuned interplay between innate and adaptive immunity—yet most approved immuno‑oncology drugs focus primarily on amplifying T‑cell (adaptive) function, risking systemic imbalance and immune‑related toxicities.
IBA101, our second‑generation CD47‑blockade antibody, is designed to safely augment innate immune surveillance while avoiding the dose‑limiting cytopenias seen with first‑generation CD47 agents; when used as monotherapy or combined with existing checkpoint inhibitors and our CD19×CD22, MSLN×CD276, and CD19×CD22×CS1 CAR‑T candidates, it has the potential to reestablish immune equilibrium and drive more effective, durable anti‑tumor responses. Through this balanced, multi‑modal approach to immunotherapy, we strive to create safer, more powerful next‑generation treatments that transform outcomes and quality of life for patients worldwide.